{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,10,18]],"date-time":"2025-10-18T00:22:16Z","timestamp":1760746936808,"version":"build-2065373602"},"reference-count":57,"publisher":"Oxford University Press (OUP)","issue":"5","license":[{"start":{"date-parts":[[2025,6,19]],"date-time":"2025-06-19T00:00:00Z","timestamp":1750291200000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":[],"published-print":{"date-parts":[[2025,10,17]]},"abstract":"<jats:title>Abstract<\/jats:title>\n               <jats:sec>\n                  <jats:title>Background<\/jats:title>\n                  <jats:p>Several population-based studies have reported an increased risk of serious skin conditions following COVID-19 vaccinations, but their population samples were not representative. Accurately estimating these risks is important for understanding vaccine hesitancy and improving clinical practice.<\/jats:p>\n               <\/jats:sec>\n               <jats:sec>\n                  <jats:title>Objectives<\/jats:title>\n                  <jats:p>To compare the incidence rates (IRs) of bullous pemphigoid (BP), herpes zoster (HZ) and urticaria before and after the UK\u2019s COVID-19 vaccination programme started.<\/jats:p>\n               <\/jats:sec>\n               <jats:sec>\n                  <jats:title>Methods<\/jats:title>\n                  <jats:p>We conducted a population-based cohort study using electronic healthcare records from the Clinical Practice Research Datalink (1 January 2019\u201331 May 2023). We estimated monthly IRs (cases\/100 000 person-years) for BP, HZ and urticaria. Using interrupted time series analysis, we compared changes in the IR slopes before and after the vaccine programme started (intervention). Sensitivity analyses were adjusted for COVID-19 lockdowns and total general practitioner (GP) appointments.<\/jats:p>\n               <\/jats:sec>\n               <jats:sec>\n                  <jats:title>Results<\/jats:title>\n                  <jats:p>In total, 16 156 639 adults (aged \u2265 18\u2005years) registered at a general practice between 1 January 2019 and 31 May 2023 (BP, n = 3506; HZ, n = 129 668; urticaria, n = 63 320). The BP IR (cases\/100 000 person-years) did not change postintervention vs. the preintervention period. We did not detect pre- and postintervention slopes. Sensitivity analysis results were similar. Preintervention, there was a downward slope for the HZ IR [\u20134.44, 95% confidence interval (CI) \u20135.54 to \u20133.35; P &amp;lt; 0.005]. The HZ IR increased postintervention vs. the preintervention period (5.15, 95% CI 3.43\u20136.88; P &amp;lt; 0.005). Despite the increase in the HZ IR, we found no evidence of a postintervention slope. Sensitivity analysis results were similar. Preintervention, there was a downward slope for the urticaria IR (\u20133.42, 95% CI \u20134.13 to \u20132.70; P &amp;lt; 0.005). The urticaria IR increased postintervention vs. the preintervention period (4.40, 95% CI 3.27\u20135.53; P &amp;lt; 0.005), resulting in an upward slope (0.98, 95% CI 0.43\u20131.52; P &amp;lt; 0.005). However, after accounting for lockdowns or GP appointments, the upward postintervention slope was no longer apparent.<\/jats:p>\n               <\/jats:sec>\n               <jats:sec>\n                  <jats:title>Conclusions<\/jats:title>\n                  <jats:p>While the BP IR did not change following the COVID-19 vaccine programme in the UK, we detected increased IRs for HZ and urticaria. However, these increases were modest, and, for many, the benefits of vaccination will probably outweigh the potential risks. Future research should use individual patient-level studies (e.g. self-controlled case series) to determine whether the increases in HZ and urticaria IRs are driven by COVID-19 vaccines.<\/jats:p>\n               <\/jats:sec>","DOI":"10.1093\/bjd\/ljaf237","type":"journal-article","created":{"date-parts":[[2025,6,27]],"date-time":"2025-06-27T17:11:42Z","timestamp":1751044302000},"page":"889-897","source":"Crossref","is-referenced-by-count":0,"title":["Incidence rates of bullous pemphigoid, herpes zoster and urticaria following the start of the COVID-19 vaccination programme in the UK: a population-based cohort study"],"prefix":"10.1093","volume":"193","author":[{"ORCID":"https:\/\/orcid.org\/0000-0001-5462-6170","authenticated-orcid":false,"given":"Mikolaj","family":"Swiderski","sequence":"first","affiliation":[{"name":"School of Medicine, University of Nottingham , Nottingham ,","place":["UK"]}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Sarah","family":"Lewis","sequence":"additional","affiliation":[{"name":"School of Medicine, University of Nottingham , Nottingham ,","place":["UK"]}],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-3030-5257","authenticated-orcid":false,"given":"Yana","family":"Vinogradova","sequence":"additional","affiliation":[{"name":"School of Medicine, University of Nottingham , Nottingham ,","place":["UK"]}],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-7954-8823","authenticated-orcid":false,"given":"Matthew J","family":"Ridd","sequence":"additional","affiliation":[{"name":"Centre for Applied Excellence in Skin & Allergy Research, University of Bristol , Bristol ,","place":["UK"]}],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-1831-074X","authenticated-orcid":false,"given":"Zenas Z N","family":"Yiu","sequence":"additional","affiliation":[{"name":"Division of Musculoskeletal and Dermatological Sciences, Faculty of Biology, Medicine and Health, NIHR Manchester Biomedical Research Centre, the University of Manchester , Manchester ,","place":["UK"]},{"name":"Department of Dermatology, Salford Royal Hospital, Northern Care Alliance NHS Foundation Trust, Manchester Academic Health Science Centre , Manchester ,","place":["UK"]}],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-2339-0596","authenticated-orcid":false,"given":"Antonia","family":"Lloyd-Lavery","sequence":"additional","affiliation":[{"name":"Department of Dermatology, Oxford University Hospitals NHS Foundation Trust , Oxford ,","place":["UK"]}],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-5470-276X","authenticated-orcid":false,"given":"Vibhore","family":"Prasad","sequence":"additional","affiliation":[{"name":"School of Medicine, University of Nottingham , Nottingham ,","place":["UK"]},{"name":"School of Life Course and Population Sciences, King\u2019s College London , London ,","place":["UK"]}],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-2443-5100","authenticated-orcid":false,"given":"Sonia","family":"Gran","sequence":"additional","affiliation":[{"name":"School of Medicine, University of Nottingham , Nottingham ,","place":["UK"]}],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"286","published-online":{"date-parts":[[2025,6,19]]},"reference":[{"key":"2025101708280176500_ljaf237-B1","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1016\/j.puhe.2021.10.008","article-title":"COVID-19 vaccination acceptability in the UK at the start of the vaccination programme: a nationally representative cross-sectional survey (CoVAccS-wave 2)","volume":"202","author":"Sherman","year":"2022","journal-title":"Public Health"},{"key":"2025101708280176500_ljaf237-B2","doi-asserted-by":"crossref","first-page":"1293","DOI":"10.1016\/S1473-3099(22)00320-6","article-title":"Global impact of the first year of COVID-19 vaccination: a mathematical modelling study","volume":"22","author":"Watson","year":"2022","journal-title":"Lancet Infect Dis"},{"key":"2025101708280176500_ljaf237-B3","doi-asserted-by":"crossref","first-page":"100012","DOI":"10.1016\/j.lanepe.2020.100012","article-title":"Attitudes towards vaccines and intention to vaccinate against COVID-19: implications for public health communications","volume":"1","author":"Paul","year":"2021","journal-title":"Lancet Reg Health Eur"},{"key":"2025101708280176500_ljaf237-B4","doi-asserted-by":"crossref","first-page":"366","DOI":"10.1038\/s41591-022-02185-4","article-title":"A survey of COVID-19 vaccine acceptance across 23 countries in 2022","volume":"29","author":"Lazarus","year":"2023","journal-title":"Nat Med"},{"key":"2025101708280176500_ljaf237-B5","doi-asserted-by":"crossref","DOI":"10.18549\/PharmPract.2021.1.2317","article-title":"Attitudes towards COVID-19 vaccination, vaccine hesitancy and intention to take the vaccine","volume":"19","author":"Cordina","year":"2021","journal-title":"Pharm Pract (Granada"},{"key":"2025101708280176500_ljaf237-B6","doi-asserted-by":"crossref","first-page":"e13891","DOI":"10.1111\/ijcp.13891","article-title":"While studies on COVID-19 vaccine is ongoing, the public's thoughts and attitudes to the future COVID-19 vaccine","volume":"75","author":"Akarsu","year":"2021","journal-title":"Int J Clin Pract"},{"key":"2025101708280176500_ljaf237-B7","doi-asserted-by":"crossref","first-page":"944","DOI":"10.3390\/vaccines9090944","article-title":"Cutaneous adverse reactions to COVID-19 vaccines: insights from an immuno-dermatological perspective","volume":"9","author":"Niebel","year":"2021","journal-title":"Vaccines (Basel"},{"key":"2025101708280176500_ljaf237-B8","doi-asserted-by":"crossref","first-page":"e15391","DOI":"10.1111\/dth.15391","article-title":"Cutaneous adverse reactions of COVID-19 vaccines: a systematic review","volume":"35","author":"Qaderi","year":"2022","journal-title":"Dermatol Ther"},{"key":"2025101708280176500_ljaf237-B9","doi-asserted-by":"crossref","first-page":"3636","DOI":"10.1111\/jocd.15261","article-title":"Cutaneous adverse reactions following COVID-19 vaccinations: a systematic review and meta-analysis","volume":"21","author":"Shafie'ei","year":"2022","journal-title":"J Cosmet Dermatol"},{"key":"2025101708280176500_ljaf237-B10","doi-asserted-by":"crossref","first-page":"172","DOI":"10.1111\/jdv.17744","article-title":"Cutaneous findings following COVID-19 vaccination: review of world literature and own experience","volume":"36","author":"Gambichler","year":"2022","journal-title":"J Eur Acad Dermatol"},{"key":"2025101708280176500_ljaf237-B11","doi-asserted-by":"crossref","first-page":"178","DOI":"10.1016\/j.jdin.2022.01.011","article-title":"Cutaneous reactions to COVID-19 vaccines: a review","volume":"7","author":"Tan","year":"2022","journal-title":"JAAD Int"},{"key":"2025101708280176500_ljaf237-B12","doi-asserted-by":"crossref","first-page":"2694","DOI":"10.1111\/bcp.14112","article-title":"Immune-mediated adverse reactions to vaccines","volume":"85","author":"Stone","year":"2019","journal-title":"Br J Clin Pharmacol"},{"key":"2025101708280176500_ljaf237-B13","doi-asserted-by":"crossref","first-page":"68","DOI":"10.1111\/bjd.19022","article-title":"Incidence, prevalence and mortality of bullous pemphigoid in England 1998\u20132017: a population-based cohort study","volume":"184","author":"Persson","year":"2021","journal-title":"Br J Dermatol"},{"key":"2025101708280176500_ljaf237-B14","first-page":"73","article-title":"Depression and anxiety in patients with bullous pemphigoid: impact and management challenges","volume":"13","author":"Kluger","year":"2020","journal-title":"Clin Cosmet Inv Derm"},{"key":"2025101708280176500_ljaf237-B15","doi-asserted-by":"crossref","DOI":"10.2340\/00015555-3457","article-title":"A systematic review of drug-induced pemphigoid","volume":"100","author":"Verheyden","year":"2020","journal-title":"Acta Derm Venereol"},{"key":"2025101708280176500_ljaf237-B16","doi-asserted-by":"crossref","first-page":"26","DOI":"10.1016\/S1473-3099(03)00857-0","article-title":"What does epidemiology tell us about risk factors for herpes zoster?","volume":"4","author":"Thomas","year":"2004","journal-title":"Lancet Infect Dis"},{"key":"2025101708280176500_ljaf237-B17","doi-asserted-by":"crossref","first-page":"e004833","DOI":"10.1136\/bmjopen-2014-004833","article-title":"Systematic review of incidence and complications of herpes zoster: towards a global perspective","volume":"4","author":"Kawai","year":"2014","journal-title":"BMJ Open"},{"key":"2025101708280176500_ljaf237-B18","doi-asserted-by":"crossref","first-page":"E6","DOI":"10.1111\/jdv.17646","article-title":"Varicella-zoster and herpes simplex virus reactivation post-COVID-19 vaccination: a review of 40 cases in an International Dermatology Registry","volume":"36","author":"Fathy","year":"2022","journal-title":"J Eur Acad Dermatol"},{"key":"2025101708280176500_ljaf237-B19","doi-asserted-by":"crossref","first-page":"572","DOI":"10.3390\/vaccines9060572","article-title":"Reactivation of varicella zoster virus after vaccination for SARS-CoV-2","volume":"9","author":"Psichogiou","year":"2021","journal-title":"Vaccines (Basel"},{"key":"2025101708280176500_ljaf237-B20","doi-asserted-by":"crossref","first-page":"572","DOI":"10.1038\/s41586-021-03653-6","article-title":"BNT162b2 vaccine induces neutralizing antibodies and poly-specific T cells in humans","volume":"595","author":"Sahin","year":"2021","journal-title":"Nature"},{"key":"2025101708280176500_ljaf237-B21","first-page":"237","article-title":"Management of chronic spontaneous urticaria: practical parameters","volume":"150","author":"Marzano","year":"2015","journal-title":"G Ital Dermatol Venereol"},{"issue":"Suppl. 2","key":"2025101708280176500_ljaf237-B22","doi-asserted-by":"crossref","first-page":"59","DOI":"10.1186\/s13223-018-0288-z","article-title":"Urticaria and angioedema","volume":"14","author":"Kanani","year":"2018","journal-title":"Allergy Asthma Clin Immunol"},{"key":"2025101708280176500_ljaf237-B23","doi-asserted-by":"crossref","first-page":"27","DOI":"10.2174\/1872213X13666190328164931","article-title":"Chronic urticaria: an overview of treatment and recent patents","volume":"13","author":"Hon","year":"2019","journal-title":"Recent Pat Inflamm Allergy Drug Discov"},{"key":"2025101708280176500_ljaf237-B24","doi-asserted-by":"crossref","first-page":"30","DOI":"10.2500\/aap.2022.43.210111","article-title":"Chronic spontaneous urticaria after BNT162b2 mRNA (Pfizer-BioNTech) vaccination against SARS-CoV-2","volume":"43","author":"Magen","year":"2022","journal-title":"Allergy Asthma Proc"},{"key":"2025101708280176500_ljaf237-B25"},{"key":"2025101708280176500_ljaf237-B26","doi-asserted-by":"crossref","first-page":"827","DOI":"10.1093\/ije\/dyv098","article-title":"Data resource profile: Clinical Practice Research Datalink (CPRD)","volume":"44","author":"Herrett","year":"2015","journal-title":"Int J Epidemiol"},{"key":"2025101708280176500_ljaf237-B27"},{"key":"2025101708280176500_ljaf237-B28","doi-asserted-by":"crossref","first-page":"443","DOI":"10.1002\/pds.1115","article-title":"The relationship between time since registration and measured incidence rates in the General Practice Research Database","volume":"14","author":"Lewis","year":"2005","journal-title":"Pharmacoepidemiol Drug Saf"},{"issue":"502","key":"2025101708280176500_ljaf237-B29","article-title":"Annual incidence rates of herpes zoster among an immunocompetent population in the United States","volume":"15","author":"Johnson","year":"2015","journal-title":"BMC Infect Dis"},{"key":"2025101708280176500_ljaf237-B30","first-page":"348","article-title":"Interrupted time series regression for the evaluation of public health interventions: a tutorial","volume":"46","author":"Bernal","year":"2017","journal-title":"Int J Epidemiol"},{"key":"2025101708280176500_ljaf237-B31","doi-asserted-by":"crossref","first-page":"346","DOI":"10.1002\/bimj.200810425","article-title":"Simultaneous inference in general parametric models","volume":"50","author":"Hothorn","year":"2008","journal-title":"Biom J"},{"key":"2025101708280176500_ljaf237-B32","doi-asserted-by":"crossref","first-page":"1111","DOI":"10.1111\/j.1365-2133.2012.11108.x","article-title":"Clinical presentation and diagnostic delay in bullous pemphigoid: a prospective nationwide cohort","volume":"167","author":"della Torre","year":"2012","journal-title":"Br J Dermatol"},{"key":"2025101708280176500_ljaf237-B33"},{"key":"2025101708280176500_ljaf237-B34"},{"key":"2025101708280176500_ljaf237-B35"},{"key":"2025101708280176500_ljaf237-B36","doi-asserted-by":"crossref","first-page":"271","DOI":"10.1111\/bjd.21240","article-title":"Evaluating risk of bullous pemphigoid after mRNA COVID-19 vaccination","volume":"187","author":"Birabaharan","year":"2022","journal-title":"Br J Dermatol"},{"key":"2025101708280176500_ljaf237-B37","doi-asserted-by":"crossref","first-page":"1342","DOI":"10.1111\/jdv.18184","article-title":"Real-world evidence from over one million COVID-19 vaccinations is consistent with reactivation of the varicella-zoster virus","volume":"36","author":"Hertel","year":"2022","journal-title":"J Eur Acad Dermatol"},{"key":"2025101708280176500_ljaf237-B38","doi-asserted-by":"crossref","first-page":"643","DOI":"10.1080\/14760584.2023.2232451","article-title":"Risk of herpes zoster following mRNA COVID-19 vaccine administration","volume":"22","author":"Florea","year":"2023","journal-title":"Expert Rev Vaccines"},{"key":"2025101708280176500_ljaf237-B39","first-page":"100393","article-title":"Herpes zoster related hospitalization after inactivated (CoronaVac) and mRNA (BNT162b2) SARS-CoV-2 vaccination: a self-controlled case series and nested case\u2013control study","volume":"21","author":"Wan","year":"2022","journal-title":"Lancet Reg Health West Pac"},{"key":"2025101708280176500_ljaf237-B40","doi-asserted-by":"crossref","first-page":"e2242240","DOI":"10.1001\/jamanetworkopen.2022.42240","article-title":"Assessment of herpes zoster risk among recipients of COVID-19 vaccine","volume":"5","author":"Akpandak","year":"2022","journal-title":"JAMA Netw Open"},{"key":"2025101708280176500_ljaf237-B41","doi-asserted-by":"crossref","first-page":"e288","DOI":"10.1016\/S2589-7500(23)00025-0","article-title":"The impact of commercial health datasets on medical research and health-care algorithms","volume":"5","author":"Alberto","year":"2023","journal-title":"Lancet Digit Health"},{"key":"2025101708280176500_ljaf237-B42","doi-asserted-by":"crossref","first-page":"3529","DOI":"10.1111\/bcp.15280","article-title":"Association study between herpes zoster reporting and mRNA COVID-19 vaccines (BNT162b2 and mRNA-1273)","volume":"88","author":"Pr\u00e9ta","year":"2022","journal-title":"Br J Clin Pharmacol"},{"key":"2025101708280176500_ljaf237-B43","doi-asserted-by":"crossref","first-page":"675","DOI":"10.1080\/14760584.2022.2044799","article-title":"Herpes zoster and simplex reactivation following COVID-19 vaccination: new insights from a vaccine adverse event reporting system (VAERS) database analysis","volume":"21","author":"Gringeri","year":"2022","journal-title":"Expert Rev Vaccines"},{"key":"2025101708280176500_ljaf237-B44","doi-asserted-by":"crossref","first-page":"4398","DOI":"10.1016\/j.vaccine.2015.07.035","article-title":"Safety monitoring in the Vaccine Adverse Event Reporting System (VAERS)","volume":"33","author":"Shimabukuro","year":"2015","journal-title":"Vaccine"},{"key":"2025101708280176500_ljaf237-B45","doi-asserted-by":"crossref","first-page":"409","DOI":"10.1177\/009286150804200501","article-title":"VigiBase, the WHO Global ICSR Database System: basic facts","volume":"42","author":"Lindquist","year":"2008","journal-title":"Drug Inf J"},{"key":"2025101708280176500_ljaf237-B46","doi-asserted-by":"crossref","first-page":"e2254298","DOI":"10.1001\/jamanetworkopen.2022.54298","article-title":"Incidence of chronic spontaneous urticaria following receipt of the COVID-19 vaccine booster in Switzerland","volume":"6","author":"Duperrex","year":"2023","journal-title":"JAMA Netw Open"},{"key":"2025101708280176500_ljaf237-B47","doi-asserted-by":"crossref","first-page":"109177","DOI":"10.1016\/j.clim.2022.109177","article-title":"Exhaustion and over-activation of immune cells in COVID-19: challenges and therapeutic opportunities","volume":"245","author":"Alahdal","year":"2022","journal-title":"Clin Immunol"},{"key":"2025101708280176500_ljaf237-B48"},{"key":"2025101708280176500_ljaf237-B49","doi-asserted-by":"crossref","first-page":"E572","DOI":"10.1111\/jdv.18890","article-title":"Risk\u2013benefit profiles associated with receiving Moderna COVID-19 (mRNA-1273) vaccine as an additional pre-booster dose in immune-mediated dermatologic disease patients with low SARS-CoV-2-specific immunity following the primary series: a prospective cohort study","volume":"37","author":"Seree-aphinan","year":"2023","journal-title":"J Eur Acad Dermatol"},{"key":"2025101708280176500_ljaf237-B50","doi-asserted-by":"crossref","DOI":"10.2340\/actadv.v104.40009","article-title":"Immunogenicity, effectiveness, and safety of COVID-19 vaccines among patients with immune-mediated dermatological diseases: a systematic review and meta-analysis","volume":"104","author":"Chirasuthat","year":"2024","journal-title":"Acta Derm Venereol"},{"key":"2025101708280176500_ljaf237-B51","doi-asserted-by":"crossref","first-page":"769845","DOI":"10.3389\/fmed.2021.769845","article-title":"Inactivated COVID-19 vaccine induces a low humoral immune response in a subset of dermatological patients receiving immunosuppressants","volume":"8","author":"Seree-Aphinan","year":"2021","journal-title":"Front Med (Lausanne)"},{"key":"2025101708280176500_ljaf237-B52","doi-asserted-by":"crossref","first-page":"268","DOI":"10.1093\/bjd\/ljac045","article-title":"A real-world prospective cohort study of immunogenicity and reactogenicity of ChAdOx1-S[recombinant] among patients with immune-mediated dermatological diseases","volume":"188","author":"Chanprapaph","year":"2023","journal-title":"Br J Dermatol"},{"key":"2025101708280176500_ljaf237-B53","doi-asserted-by":"crossref","first-page":"2005","DOI":"10.1111\/all.13209","article-title":"The burden of chronic spontaneous urticaria is substantial: real-world evidence from ASSURE-CSU","volume":"72","author":"Maurer","year":"2017","journal-title":"Allergy"},{"key":"2025101708280176500_ljaf237-B54","doi-asserted-by":"crossref","first-page":"1393","DOI":"10.1111\/all.13397","article-title":"The EAACI\/GA2LEN\/EDF\/WAO guideline for the definition, classification, diagnosis and management of urticaria","volume":"73","author":"Zuberbier","year":"2018","journal-title":"Allergy"},{"author":"British Association of Dermatologists","key":"2025101708280176500_ljaf237-B55"},{"key":"2025101708280176500_ljaf237-B56","doi-asserted-by":"crossref","DOI":"10.1093\/ofid\/ofac118","article-title":"Increased risk of herpes zoster in adults \u226550\u2005years old diagnosed with COVID-19 in the United States","volume":"9","author":"Bhavsar","year":"2022","journal-title":"Open Forum Infect Dis"},{"key":"2025101708280176500_ljaf237-B57","doi-asserted-by":"crossref","first-page":"102154","DOI":"10.1016\/j.eclinm.2023.102154","article-title":"Risk of autoimmune diseases following COVID-19 and the potential protective effect from vaccination: a population based cohort study","volume":"63","author":"Peng","year":"2023","journal-title":"EClinicalMedicine"}],"container-title":["British Journal of Dermatology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/academic.oup.com\/bjd\/advance-article-pdf\/doi\/10.1093\/bjd\/ljaf237\/63528635\/ljaf237.pdf","content-type":"application\/pdf","content-version":"am","intended-application":"syndication"},{"URL":"https:\/\/academic.oup.com\/bjd\/article-pdf\/193\/5\/889\/63528635\/ljaf237.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"syndication"},{"URL":"https:\/\/academic.oup.com\/bjd\/article-pdf\/193\/5\/889\/63528635\/ljaf237.pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,10,17]],"date-time":"2025-10-17T12:28:13Z","timestamp":1760704093000},"score":1,"resource":{"primary":{"URL":"https:\/\/academic.oup.com\/bjd\/article\/193\/5\/889\/8169428"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,6,19]]},"references-count":57,"journal-issue":{"issue":"5","published-online":{"date-parts":[[2025,6,19]]},"published-print":{"date-parts":[[2025,10,17]]}},"URL":"https:\/\/doi.org\/10.1093\/bjd\/ljaf237","relation":{},"ISSN":["0007-0963","1365-2133"],"issn-type":[{"type":"print","value":"0007-0963"},{"type":"electronic","value":"1365-2133"}],"subject":[],"published-other":{"date-parts":[[2025,11]]},"published":{"date-parts":[[2025,6,19]]}}}